Ozempic Gastroparesis Settlement: Statute of Limitations for Ozempic in Pennsylvania

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Legal Awareness

The legacy of general health and science information has long provided a foundation for public understanding of medication risks and legal recourse. In this tradition, the focus has been on broad educational outreach, ensuring that individuals are aware of potential side effects and their rights to seek compensation. As we pivot from this general health context to a more specific occupational exposure concern, the transition involves recognizing how widely prescribed medications can lead to unforeseen complications. Ozempic, a drug originally developed for diabetes management, has been associated with gastroparesis—a condition affecting stomach muscle function. This concern has prompted legal inquiries, particularly regarding the statute of limitations for filing claims in Pennsylvania. The shift from general health education to targeted legal awareness requires understanding that exposure to such medications, whether through personal use or occupational handling, may carry risks that necessitate timely action. The bridge concept here is the evolution from passive receipt of health information to active engagement with legal timelines, emphasizing that awareness of potential harm must be paired with knowledge of procedural deadlines. This transition underscores the importance of translating general health knowledge into specific, actionable steps for those affected by Ozempic-related gastroparesis.

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a chronic disorder characterized by delayed gastric emptying in the absence of mechanical obstruction. Clinical presentation includes early satiety, postprandial fullness, nausea, vomiting, and abdominal pain. Diagnosis is typically confirmed through gastric emptying scintigraphy, which measures the rate at which a radiolabeled meal leaves the stomach. The condition can significantly impair quality of life and lead to nutritional deficiencies, weight loss, and hospitalizations. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes. Its pharmacology involves slowing gastric emptying, which contributes to glycemic control and weight loss. However, this mechanism also underlies its gastrointestinal adverse effects. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Pathways and Warning Adequacy

Mechanistic pathways linking Ozempic to gastroparesis are well-established. GLP-1 receptor agonists delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This pharmacodynamic effect is intended but can become pathological in susceptible individuals, leading to symptomatic gastroparesis. Postmarketing reports have documented pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the severity of delayed gastric emptying associated with these drugs. The adequacy of warnings regarding Ozempic and gastroparesis is a central risk anchor. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions and hypersensitivity reactions, including anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not explicitly warn of gastroparesis as a distinct adverse event. The warning about pulmonary aspiration in patients undergoing surgery is included in the label for Rybelsus and Ozempic tablets, but it is not specific to gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This gap in explicit warning may affect legal claims regarding failure to adequately inform patients and prescribers of the risk of developing gastroparesis.

Statute of Limitations for Ozempic Claims in Pennsylvania

Settlement-related considerations for affected patients in Pennsylvania involve the statute of limitations. In Pennsylvania, the statute of limitations for personal injury claims, including product liability and medical malpractice, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. For gastroparesis allegedly caused by Ozempic, the clock typically starts when the patient is diagnosed or when symptoms become severe enough to prompt medical evaluation. The timeline between exposure and documented harm is critical. Gastrointestinal symptoms often emerge during dose escalation, but gastroparesis may develop insidiously over months or years of use. Patients who experienced persistent nausea, vomiting, or abdominal pain while on Ozempic should have been evaluated for gastroparesis. The delay in diagnosis can affect the statute of limitations, as the discovery rule may extend the filing deadline if the injury was not immediately apparent. Patients considering a settlement should document the date of first Ozempic use, the onset of gastrointestinal symptoms, and the date of gastroparesis diagnosis. Medical records confirming the diagnosis through gastric emptying scintigraphy are essential. The adequacy of warnings will be a key factor in settlement negotiations. If the manufacturer failed to warn of the specific risk of gastroparesis, this may strengthen the claim. However, the presence of general gastrointestinal adverse reaction warnings may be used to argue that the risk was foreseeable. In summary, Pennsylvania patients with Ozempic-related gastroparesis face a two-year statute of limitations from the date of discovery. The mechanistic link between Ozempic and delayed gastric emptying is supported by clinical trial data and postmarketing reports. The adequacy of warnings remains a contested issue, as the label does not explicitly mention gastroparesis. Patients should seek legal counsel promptly to preserve their rights.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Pennsylvania?

In Pennsylvania, the statute of limitations for personal injury claims, including product liability and medical malpractice, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. For Ozempic-related gastroparesis, the clock typically starts when the patient is diagnosed or when symptoms become severe enough to prompt medical evaluation.

Does Ozempic's label explicitly warn about gastroparesis?

No, the prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions and hypersensitivity reactions, but it does not explicitly warn of gastroparesis as a distinct adverse event. This gap may affect legal claims regarding failure to adequately inform patients and prescribers of the risk of developing gastroparesis.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.